A detailed history of Price T Rowe Associates Inc transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 31,458 shares of OLMA stock, worth $271,482. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,458
Previous 31,242 0.69%
Holding current value
$271,482
Previous $339,000 10.91%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.41 - $16.46 $2,248 - $3,555
216 Added 0.69%
31,458 $376,000
Q2 2024

Aug 14, 2024

BUY
$8.73 - $13.99 $43,571 - $69,824
4,991 Added 19.01%
31,242 $339,000
Q1 2024

May 15, 2024

BUY
$10.95 - $16.62 $16,271 - $24,697
1,486 Added 6.0%
26,251 $298,000
Q4 2023

Feb 14, 2024

SELL
$10.53 - $17.14 $148,272 - $241,348
-14,081 Reduced 36.25%
24,765 $348,000
Q3 2023

Nov 14, 2023

SELL
$8.19 - $12.98 $180,237 - $285,650
-22,007 Reduced 36.16%
38,846 $480,000
Q2 2023

Aug 14, 2023

BUY
$3.22 - $9.65 $8,220 - $24,636
2,553 Added 4.38%
60,853 $550,000
Q1 2023

May 15, 2023

SELL
$2.55 - $4.97 $26,010 - $50,694
-10,200 Reduced 14.89%
58,300 $203,000
Q2 2022

Aug 15, 2022

SELL
$2.04 - $4.61 $4,838 - $10,934
-2,372 Reduced 3.35%
68,500 $279,000
Q1 2022

May 16, 2022

BUY
$3.89 - $9.43 $2,723 - $6,601
700 Added 1.0%
70,872 $302,000
Q4 2021

Feb 14, 2022

BUY
$8.75 - $30.71 $614,005 - $2.15 Million
70,172 New
70,172 $657,000
Q3 2021

Nov 15, 2021

SELL
$22.96 - $30.13 $197,984 - $259,810
-8,623 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$21.15 - $36.14 $3,658 - $6,252
173 Added 2.05%
8,623 $241,000
Q1 2021

May 17, 2021

BUY
$27.81 - $53.64 $234,994 - $453,258
8,450 New
8,450 $280,000

Others Institutions Holding OLMA

About Olema Pharmaceuticals, Inc.


  • Ticker OLMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,419,600
  • Market Cap $349M
  • Description
  • Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...
More about OLMA
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.